The near-dormant global market for urinary incontinence treatments is poised to erupt in the second half of this decade-Novartis' recent acquisition of Pfizer's darifenacin introduces one more global player to the mix. But for existing and novel drug therapies to succeed in the fragmented and particularly underdeveloped European market companies must first recognize the challenges presented by cultural taboo and country-specific regulation.
Novartis AG 's task will not be easy.
Johnson & Johnson 's extended-release oxybutynin (Ditropan XL) and Pfizer Inc. 's tolterodine (Detrol/Detrusitol, developed and marketed by...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
